Cover Image
市場調查報告書

腎臟生物標記:技術和全球市場

Renal Biomarkers: Technologies and Global Markets

出版商 BCC Research 商品編碼 320188
出版日期 內容資訊 英文 90 Pages
訂單完成後即時交付
價格
Back to Top
腎臟生物標記:技術和全球市場 Renal Biomarkers: Technologies and Global Markets
出版日期: 2015年01月01日 內容資訊: 英文 90 Pages
簡介

體外診斷的腎臟生物標記市場2013年記錄為7億7,100萬美元,2014年為8億1,200萬美元的規模。從2014年到2019年,預計以7%的年複合成長率發展,2019年達到11億美元的規模。

本報告提供腎臟生物標記的市場及技術的相關調查、腎臟疾病的背景及流行病學、腎臟生物標記概要、專利、價格、償付等趨勢、市場規模的變化與預測、各地區、化驗、疾病種類的詳細內容、診斷化驗的主要製造商與市場佔有率、主要企業簡介、主要產品、企業策略等彙整資料。

第1章 簡介

第2章 摘要

第3章 概要

  • 腎臟疾病的背景
    • 症狀
    • 診斷
    • 分類
    • 急性腎功能衰竭的治療
    • 急性腎損傷和慢性腎臟病的相關性
    • 心血管和腎臟疾病的相關性
  • 腎臟疾病的流行病學
    • 估計GFR的減少
  • 全球腎透析設備、設備市場收益分析
    • 全球市場的摘要
    • 透析的階段性轉移的人工腎臟
    • 可攜式、插裝式的血液透析機設備
    • 穿戴式腹膜透析設備
  • 價格及償付趨勢
    • 美國
    • 加拿大
    • 日本
    • 德國
    • 法國
    • 義大利
    • 英國
    • 巴西
    • 其他國:中國、印度、西班牙
    • 腎臟生物標記的未來方向性
    • 腎臟生物標記的臨床性價值
    • 生物標記的臨床性評估

第4章 產業結構與競爭分析

  • 產業結構
    • 診斷手法
  • 重新發行的專利
  • 各生物標記
  • 各製造商、研究機關
  • 新的專利申請
  • 各部門
  • 政府的法律規章
  • 一般技術課題
    • 選擇性和特異性
    • 正、負的預測值
    • ROC(接收者操作特性)曲線

第5章 各化驗市場

  • 摘要

第6章 各地區市場

  • 摘要
  • 美國市場
  • 歐洲市場
  • 中國市場
  • 中南美市場
  • 其他地區

第7章 企業簡介

  • 主要企業市場佔有率
  • ABBOTT DIAGNOSTICS
  • AFFYMETRIX INC.
  • ALERE
  • ASTUTE MEDICAL INC.
  • BECKMAN COULTER
  • BECTON, DICKINSON AND COMPANY
  • BG MEDICINE INC.
  • BIOMERIEUX
  • BIOPHYSICAL CORP.
  • CORRELOGIC SYSTEMS INC.
  • RADIOMETER MEDICAL
  • RANDOX LABORATORY
  • RESPONSE BIOMEDICAL CORP.
  • ROCHE HOLDING AG
  • SIEMENS HEALTHCARE
  • SINGULEX
  • THERMO FISHER SCIENTIFIC

圖表

目錄
Product Code: BIO138A

REPORT HIGHLIGHTS

The in vitro diagnostic renal biomarker market was valued at $771 million in 2013 and $812 million in 2014. The market is expected to reach $1.1 billion by 2019, a compound annual growth rate (CAGR) of 7% from 2014 to 2019.

This report provides:

  • A comprehensive analysis of renal biomarkers global markets and technologies.
  • Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
  • Details pertaining to the history and current state of chronic kidney disease (CKD), background information on renal biomarkers, and current industrial technologies used for diagnosis.
  • In-depth analyses of the predominant biomarkers in the market, namely creatinine, and emerging biomarkers like NGAL, KIM-1, L-FABP and many others.
  • Discussion concerning intellectual property, the regulatory requirement, and the competitive landscape of the industry.
  • Comprehensive profiles of major players in the renal biomarkers field.

SCOPE OF REPORT

The report presents current and projected assay forecasts during the forecast period (2014 to 2019). In addition, the study also includes emerging assays with regulatory approval and others expected to achieve Food and Drug Administration (FDA) approved by 2015 within the forecast period. Estimates are used for 2014, except in cases where actual results have been reported. For large market segments such as creatinine and cystatin C, the report discusses their analytical sensitivities and cutoff references in detail, as well as the glomerular filtration rate estimation for diagnosis and prognosis values. The study also focuses on ongoing efforts in developing biomarkers for acute kidney injury.

The report includes analysis of leading and emerging competitors in the current worldwide diagnostic market for kidney diseases. Profiles of manufacturers of leading products as well as biotechnology companies with products in development are discussed, along with their specific product strategies. Detailed profiles of current market leaders are included, as well as profiles of companies with innovative products poised to advance within the forecast period. Market figures are based on revenues at the manufacturers' level and are projected at 2014-dollar value. Inflation is not computed into projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products, and projected changes in the prevalence of diagnosis for respective diseases. In addition, the report includes forecasts by product, product category and company from 2013 through 2019. The study is arranged to offer an overview of the diagnostic market accompanied by product, company and region.

Excluded from this report are non-proteomic diagnoses (i.e., molecular diagnostics), imagining technology or pharmaceutical biomarkers. Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of sales change. Sales figures do not account for variation in local currencies. All market share data presented is on a global basis, unless specifically noted.

ANALYST'S CREDENTIALS

Cheng-Yuk Lee is a life sciences researcher and engineer. He has experience in preclinical and translational medicine research in a pharmaceutical company and led several assay developments as a scientist in a private in vitro diagnostic company with campuses in China and the U.S. He received a dual Bachelor of Science degree in chemical engineering and biochemistry and subsequently completed his Ph.D. in chemical engineering and post-doctoral training. Prior to his professional career, he provided marketing research and strategic business planning for the Office of Corporate Relations at a public research university.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • METHODOLOGY AND INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: RENAL BIOMARKER MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE A: RENAL BIOMARKER MARKET BY REGION, 2013-2019 ($ MILLIONS)
  • SUMMARY FIGURE B: ESTIMATED GLOBAL POPULATION WITH RENAL DISEASE, 2013-2019 (NO. OF CASES)

CHAPTER 3 - OVERVIEW

  • BACKGROUND OF RENAL DISEASE
    • FIGURE 1: CLASSIFICATION OF ACUTE KIDNEY INJURY
    • SYMPTOMS
    • DIAGNOSIS
    • CLASSIFICATION OF KIDNEY INJURY AND DISEASE
      • TABLE 1: DEFINITION CRITERIA FOR KIDNEY INJURY/DISEASE
    • TREATMENT FOR ACUTE KIDNEY FAILURE
    • RELATIONSHIP BETWEEN ACUTE KIDNEY INJURY AND CHRONIC KIDNEY DISEASE
      • FIGURE 2: POTENTIAL OUTCOMES OF ACUTE KIDNEY INJURY
    • CONNECTION BETWEEN CARDIOVASCULAR AND RENAL DISEASE
  • EPIDEMIOLOGY OF RENAL DISEASE
    • DECREASED ESTIMATED GFR
      • TABLE 2: STAGES OF CHRONIC KIDNEY DISEASE
      • FIGURE 3: NUMBER OF HOSPITALIZATIONS WITH ACUTE KIDNEY INJURY, FROM 1979-2002
      • FIGURE 4: TRENDS OF KIDNEY DISEASE INCIDENT RATE IN THE U.S., FROM 1980-2005
      • TABLE 3: INCIDENCE OF ESRD BY COUNTRY, 2011 (PER MILLION POPULATION)
      • TABLE 4: PREVALENCE OF ESRD BY COUNTRY, 2011
      • TABLE 5: PERCENTAGE OF INCIDENT ESRD PATIENTS DUE TO DIABETES BY COUNTRY, 2011 (%)
      • TABLE 6: KIDNEY TRANSPLANT RATES BY COUNTRY, 2011 (RATE IN PATIENTS PER MILLION)
  • REVENUE ANALYSIS OF THE GLOBAL RENAL DIALYSIS EQUIPMENT AND ACCESSORIES MARKET
    • GLOBAL MARKET SUMMARY
      • TABLE 7: GLOBAL MARKET FOR RENAL DIALYSIS EQUIPMENT AND ACCESSORIES, THROUGH 2018 ($ MILLIONS)
      • TABLE 8: SHARE OF THE RENAL DIALYSIS EQUIPMENT AND ACCESSORIES MARKET BY PRODUCT SEGMENT, 2013 AND 2018 (%)
      • TABLE 9: SHARE OF THE TOTAL DIALYSIS EQUIPMENT AND ACCESSORIES MARKET BY REGION, 2013 AND 2018 (%)
    • ARTIFICIAL KIDNEYS FOR GRADUAL REPLACEMENT OF DIALYSIS
    • PORTABLE, CARTRIDGE-BASED HEMODIALYSIS DEVICE
    • WEARABLE PERITONEAL DIALYSIS DEVICE
  • PRICING AND REIMBURSEMENT TRENDS
    • TABLE 10: REIMBURSEMENT OF DIALYSIS SERVICES PER WEEK BY SELECTED COUNTRIES, 2011-2013 ($)
    • THE U.S.
    • CANADA
    • JAPAN
    • GERMANY
    • FRANCE
    • ITALY
    • THE U.K.
    • BRAZIL
    • OTHER COUNTRIES-CHINA, INDIA AND SPAIN
    • FUTURE DIRECTION OF RENAL BIOMARKERS
    • CLINICAL VALUES OF RENAL BIOMARKERS
      • Alpha-1/Beta2-microglobulin
      • Alanine-aminopeptidase (Ala-AP)
      • Alkaline Phosphatase (ALP)
      • Albumin
      • Calprotectin
      • Clusterin
      • Creatinine
      • Cystatin C
      • FGF23
      • Hepcidin
      • Interleukin-18 (IL-18)
      • Kidney Injury Molecule-1 (KIM-1)
      • Liver Fatty Acid-Binding Protein (L-FABP)
      • N-acetyl-beta-D-Glucosaminidase (NAG)
      • Netrin
      • Neutrophil Gelatinase-Associated Lipocalin (NGAL)
      • Retinol Binding Protein (RBP)
      • Sodium/Hydrogen Exchanger Isoform 3 (NHE3)
      • Tissue Inhibitors of Metalloproteinases-2 (TIMP-2)
      • Trefoil Factor 3 (TFF3)
      • Gamma-Glutamyl Transpeptidase
    • CLINICAL EVALUATION OF BIOMARKERS
      • Glomerular Filtration Rate (GFR)

CHAPTER 4 - INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS

  • INDUSTRY STRUCTURE
    • DIAGNOSTIC METHODS
      • Immunoassay
        • Radioimmunoassay
        • ELISA
        • Chemiluminescent Enzyme Immunoassay
        • Light Scattering
        • Turbidimetry
        • Nephelometry
        • Particle Counting
        • New Developments
        • Liquid Chromatography-Mass Spectrometry
  • NEWLY ISSUED PATENTS
    • TABLE 11: RENAL BIOMARKER DIAGNOSIS ASSAY PATENT TRENDS, 2010-2014 (NO. OF PATENTS)
  • BY BIOMARKERS
    • TABLE 12: PATENTS BY BIOMARKERS, 2010-2014
  • BY MANUFACTURER/RESEARCH INSTITUTE
    • TABLE 13: PATENTS BY COMPANY/INSTITUTION, 2010-2014 (NO. OF PATENTS/%)
    • TABLE 14: PATENTS FOR RENAL BIOMARKER DIAGNOSIS ASSAY, 2014
    • TABLE 15: RENAL BIOMARKER DIAGNOSIS PATENT ORIGIN, FROM 2012-MAY 2014 (NO. OF PATENTS/%)
  • NEW PATENT APPLICATIONS
    • TABLE 16: PATENT APPLICATIONS BY BIOMARKERS, 2012-MAY 2014 (NO. OF PATENT APPLICATIONS/%)
    • TABLE 17: EXAMPLES OF PATENT APPLICATION BY COMPANY, JAN-MAY 2014
    • TABLE 18: RENAL BIOMARKER DIAGNOSIS PATENT ORIGIN, FROM 2012-MAY 2014 (NO. OF PATENTS/%)
  • BY SECTOR
    • TABLE 19: PATENT APPLICATIONS BY COMPANY, AUG-OCT, 2013
  • GOVERNMENT REGULATION
    • U.S. FDA 510(K) APPROVAL
      • Division Acceptance and Review
    • CE MARKING IN EUROPE
    • OTHER INTERNATIONAL REGULATORY AGENCIES
    • TRENDS IN PRICE AND PRICE/PERFORMANCE
  • GENERAL TECHNOLOGY ISSUES
    • SELECTIVITY AND SPECIFICITY
    • POSITIVE AND NEGATIVE PREDICTIVE VALUES
    • RECEIVER OPERATOR CHARACTERISTIC CURVES

CHAPTER 5 - MARKET BY ASSAYS

  • SUMMARY OF MARKET BY ASSAYS
    • TABLE 20: GLOBAL RENAL BIOMARKER MARKET BY ASSAY, THROUGH 2019 ($ MILLIONS)
    • TABLE 21: GLOBAL RENAL BIOMARKER MARKET BY INSTRUMENT, THROUGH 2019 ($ MILLIONS)
    • TABLE 22: GLOBAL CREATININE BIOMARKER MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)

CHAPTER 6 - MARKET BY REGION

  • SUMMARY OF MARKET BY REGION
    • TABLE 23: ACUTE KIDNEY INJURY BIOMARKER MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 24: CHRONIC KIDNEY DISEASE BIOMARKER MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • U.S. MARKET
    • TABLE 25: U.S. PATIENT POPULATION WITH RENAL DISEASE, THROUGH 2019 (CASES)
    • TABLE 26: U.S. MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)
    • TABLE 27: U.S. RENAL BIOMARKER MARKET BY ASSAY, THROUGH 2019 ($ MILLIONS)
    • TABLE 28: U.S. CREATININE BIOMARKER MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)
  • EUROPEAN MARKET
    • TABLE 29: EUROPE PATIENT POPULATION WITH RENAL DISEASE, THROUGH 2019 (CASES)
    • TABLE 30: EUROPE MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)
    • TABLE 31: EUROPE RENAL BIOMARKER MARKET BY ASSAY, THROUGH 2019 ($ MILLIONS)
    • TABLE 32: EUROPE CREATININE BIOMARKER MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)
  • CHINESE MARKET
    • TABLE 33: CHINA PATIENT POPULATION WITH RENAL DISEASE, THROUGH 2019 (CASES)*
    • TABLE 34: CHINA MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)
    • TABLE 35: CHINA RENAL BIOMARKER MARKET BY ASSAY, THROUGH 2019 ($ MILLIONS)
    • TABLE 36: CHINA CREATININE BIOMARKER MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)
  • CENTRAL AND SOUTH AMERICA MARKET
    • TABLE 37: CENTRAL AND SOUTH AMERICA PATIENT POPULATION WITH RENAL DISEASE, THROUGH 2019 (CASES)
    • TABLE 38: CENTRAL AND SOUTH AMERICA MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)
    • TABLE 39v CENTRAL AND SOUTH AMERICA RENAL BIOMARKER MARKET BY ASSAY, THROUGH 2019 ($ MILLIONS)*
    • TABLE 40: CENTRAL AND SOUTH AMERICA CREATININE BIOMARKER MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)
  • REST OF THE WORLD (ROW) MARKET
    • TABLE 41: REST OF THE WORLD PATIENT POPULATION WITH RENAL DISEASE, THROUGH 2019 (CASES)
    • TABLE 42: REST OF THE WORLD MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)
    • TABLE 43: REST OF THE WORLD RENAL BIOMARKER MARKET BY ASSAY, THROUGH 2019 ($ MILLIONS)
    • TABLE 44: REST OF THE WORLD CREATININE BIOMARKER MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)

CHAPTER 7 - COMPANY PROFILES

  • MAJOR COMPANIES AND MARKET SHARE
    • TABLE 45: MANUFACTURERS OF DIAGNOSTICS ASSAYS GLOBAL SALES, 2012 ($ MILLIONS/%)
    • TABLE 46: MANUFACTURERS OF DIAGNOSTICS ASSAYS, NORTH AMERICA SALES, 2012 ($ MILLIONS/%)
    • TABLE 47: MANUFACTURERS OF DIAGNOSTICS ASSAYS, EUROPE SALES, 2012 ($ MILLIONS)
    • TABLE 48: MANUFACTURERS OF DIAGNOSTICS ASSAYS ASIA SALES, 2012 ($ MILLIONS/%)
    • TABLE 49: MANUFACTURERS OF DIAGNOSTICS ASSAYS REST OF THE WORLD SALES, 2012 ($ MILLIONS/%)
  • ABBOTT DIAGNOSTICS
    • KEY PRODUCTS
    • COMPANY STRATEGY
  • AFFYMETRIX INC.
    • KEY PRODUCTS
  • ALERE
    • KEY PRODUCTS
  • ASTUTE MEDICAL INC.
    • KEY PRODUCT
  • BECKMAN COULTER
    • KEY PRODUCTS
  • BECTON, DICKINSON AND COMPANY
  • BG MEDICINE INC.
    • KEY PRODUCTS
    • COMPANY STRATEGY
  • BIOMERIEUX
  • BIOPHYSICAL CORP.
    • KEY PRODUCTS
    • COMPANY STRATEGY
  • CORRELOGIC SYSTEMS INC.
    • KEY PRODUCTS
    • COMPANY STRATEGY
  • RADIOMETER MEDICAL
    • KEY PRODUCT
  • RANDOX LABORATORY
    • KEY PRODUCTS
  • RESPONSE BIOMEDICAL CORP.
    • KEY PRODUCTS
  • ROCHE HOLDING AG
    • KEY PRODUCTS
    • COMPANY STRATEGY
  • SIEMENS HEALTHCARE
    • KEY PRODUCTS
  • SINGULEX
    • KEY PRODUCT
  • THERMO FISHER SCIENTIFIC
    • KEY PRODUCTS

LIST OF TABLES

  • SUMMARY TABLE: RENAL BIOMARKER MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 1: DEFINITION CRITERIA FOR KIDNEY INJURY/DISEASE
    • TABLE 2: STAGES OF CHRONIC KIDNEY DISEASE
    • TABLE 3: INCIDENCE OF ESRD BY COUNTRY, 2011 (PER MILLION POPULATION)
    • TABLE 4: PREVALENCE OF ESRD BY COUNTRY, 2011
    • TABLE 5: PERCENTAGE OF INCIDENT ESRD PATIENTS DUE TO DIABETES BY COUNTRY, 2011 (%)
    • TABLE 6: KIDNEY TRANSPLANT RATES BY COUNTRY, 2011 (RATE IN PATIENTS PER MILLION)
    • TABLE 7: GLOBAL MARKET FOR RENAL DIALYSIS EQUIPMENT AND ACCESSORIES, THROUGH 2018 ($ MILLIONS)
    • TABLE 8: SHARE OF THE RENAL DIALYSIS EQUIPMENT AND ACCESSORIES MARKET BY PRODUCT SEGMENT, 2013 AND 2018 (%)
    • TABLE 9: SHARE OF THE TOTAL DIALYSIS EQUIPMENT AND ACCESSORIES MARKET BY REGION, 2013 AND 2018 (%)
    • TABLE 10: REIMBURSEMENT OF DIALYSIS SERVICES PER WEEK BY SELECTED COUNTRIES, 2011-2013 ($)
    • TABLE 11: RENAL BIOMARKER DIAGNOSIS ASSAY PATENT TRENDS, 2010-2014 (NO. OF PATENTS)
    • TABLE 12: PATENTS BY BIOMARKERS, 2010-2014
    • TABLE 13: PATENTS BY COMPANY/INSTITUTION, 2010-2014 (NO. OF PATENTS/%)
    • TABLE 14: PATENTS FOR RENAL BIOMARKER DIAGNOSIS ASSAY, 2014
    • TABLE 15: RENAL BIOMARKER DIAGNOSIS PATENT ORIGIN, FROM 2012-MAY 2014 (NO. OF PATENTS/%)
    • TABLE 16: PATENT APPLICATIONS BY BIOMARKERS, 2012-MAY 2014 (NO. OF PATENT APPLICATIONS/%)
    • TABLE 17: EXAMPLES OF PATENT APPLICATION BY COMPANY, JAN-MAY 2014
    • TABLE 18: RENAL BIOMARKER DIAGNOSIS PATENT ORIGIN, FROM 2012-MAY 2014 (NO. OF PATENTS/%)
    • TABLE 19: PATENT APPLICATIONS BY COMPANY, AUG-OCT, 2013
    • TABLE 20: GLOBAL RENAL BIOMARKER MARKET BY ASSAY, THROUGH 2019 ($ MILLIONS)
    • TABLE 21: GLOBAL RENAL BIOMARKER MARKET BY INSTRUMENT, THROUGH 2019 ($ MILLIONS)
    • TABLE 22: GLOBAL CREATININE BIOMARKER MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)
    • TABLE 23: ACUTE KIDNEY INJURY BIOMARKER MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 24: CHRONIC KIDNEY DISEASE BIOMARKER MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 25: U.S. PATIENT POPULATION WITH RENAL DISEASE, THROUGH 2019 (CASES)
    • TABLE 26: U.S. MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)
    • TABLE 27: U.S. RENAL BIOMARKER MARKET BY ASSAY, THROUGH 2019 ($ MILLIONS)
    • TABLE 28: U.S. CREATININE BIOMARKER MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)
    • TABLE 29: EUROPE PATIENT POPULATION WITH RENAL DISEASE, THROUGH 2019 (CASES)
    • TABLE 30: EUROPE MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)
    • TABLE 31: EUROPE RENAL BIOMARKER MARKET BY ASSAY, THROUGH 2019 ($ MILLIONS)
    • TABLE 32: EUROPE CREATININE BIOMARKER MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)
    • TABLE 33: CHINA PATIENT POPULATION WITH RENAL DISEASE, THROUGH 2019 (CASES)*
    • TABLE 34: CHINA MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)
    • TABLE 35: CHINA RENAL BIOMARKER MARKET BY ASSAY, THROUGH 2019 ($ MILLIONS)
    • TABLE 36: CHINA CREATININE BIOMARKER MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)
    • TABLE 37: CENTRAL AND SOUTH AMERICA PATIENT POPULATION WITH RENAL DISEASE, THROUGH 2019 (CASES)
    • TABLE 38: CENTRAL AND SOUTH AMERICA MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)
    • TABLE 39: CENTRAL AND SOUTH AMERICA RENAL BIOMARKER MARKET BY ASSAY, THROUGH 2019 ($ MILLIONS)*
    • TABLE 40: CENTRAL AND SOUTH AMERICA CREATININE BIOMARKER MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)
    • TABLE 41: REST OF THE WORLD PATIENT POPULATION WITH RENAL DISEASE, THROUGH 2019 (CASES)
    • TABLE 42: REST OF THE WORLD MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)
    • TABLE 43: REST OF THE WORLD RENAL BIOMARKER MARKET BY ASSAY, THROUGH 2019 ($ MILLIONS)
    • TABLE 44: REST OF THE WORLD CREATININE BIOMARKER MARKET BY RENAL DISEASE, THROUGH 2019 ($ MILLIONS)
    • TABLE 45: MANUFACTURERS OF DIAGNOSTICS ASSAYS GLOBAL SALES, 2012 ($ MILLIONS/%)
    • TABLE 46: MANUFACTURERS OF DIAGNOSTICS ASSAYS, NORTH AMERICA SALES, 2012 ($ MILLIONS/%)
    • TABLE 47: MANUFACTURERS OF DIAGNOSTICS ASSAYS, EUROPE SALES, 2012 ($ MILLIONS)
    • TABLE 48: MANUFACTURERS OF DIAGNOSTICS ASSAYS ASIA SALES, 2012 ($ MILLIONS/%)
    • TABLE 49: MANUFACTURERS OF DIAGNOSTICS ASSAYS REST OF THE WORLD SALES, 2012 ($ MILLIONS/%)

LIST OF FIGURES

  • SUMMARY FIGURE A: RENAL BIOMARKER MARKET BY REGION, 2013-2019 ($ MILLIONS)
  • SUMMARY FIGURE B: ESTIMATED GLOBAL POPULATION WITH RENAL DISEASE, 2013-2019 (NO. OF CASES)
    • FIGURE 1: CLASSIFICATION OF ACUTE KIDNEY INJURY
    • FIGURE 2: POTENTIAL OUTCOMES OF ACUTE KIDNEY INJURY
    • FIGURE 3: NUMBER OF HOSPITALIZATIONS WITH ACUTE KIDNEY INJURY, FROM 1979-2002
    • FIGURE 4: TRENDS OF KIDNEY DISEASE INCIDENT RATE IN THE U.S., FROM 1980-2005
Back to Top